The number of rAAV vectors needed to treat a tissue such ... capable of meeting global patient demand. The expertise in packaging and cold supply chain management that Pfizer developed in support ...

Accordingly, the large majority of recombinant adeno-associated virus (rAAV)-based therapies—which account for most gene therapies—are still produced with a method developed more than two ...